Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome.

Hannah Cohen, Maria Efthymiou, Carolyn Gates, David Isenberg

Journal: Seminars in thrombosis and hemostasis 2018;44(5):427-438

PMID: 28196381

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS) is anticoagulation with warfarin or other vitamin K antagonists (VKAs). In addition to their well-known limitations, VKAs are often problematic in APS patients because of the variable sensitivity of thromboplastins to lupus anticoagulant. As a result, the international normalized ratio may not accurately reflect the intensity of anticoagulation. Direct oral anticoagulants (DOACs) are established as therapeutic alternatives to VKAs for a wide range of indications, including the treatment and secondary prevention of venous thromboembolism. Definition of the role of DOACs in the treatment of thrombotic APS is emerging with the results of recent and ongoing clinical studies. This review focuses on the current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues pertinent to DOAC use in APS patients, as well as potential future directions.

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Address: Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom.; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Department of Pharmacy, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom.; Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

DOI: 10.1055/s-0036-1597902